Latest & greatest articles for alzheimer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Alzheimer’s disease

Alzheimer’s disease is a chronic neurodegenerative disease responsible for the majority of cases of dementia. This progressive disease disrupts memory and thinking due to an accumulation of plaques and tangles in the brain. As the disease progresses, these get progressively worse.

What causes Alzheimer’s diseases is poorly understood, although there is a strong genetic component which could account for the majority (~70%) of the risk. Other risk factors have been identified, such as depression, head injuries and hypertension. Alzheimer’s disease is typically a disease of older people.

Although Alzheimer’s disease cannot currently be cured but it can be managed. With cholinesterase inhibitors being a common intervention as well as memantine (an NMDA receptor antagonist) and psychosocial interventions.

Trip has an extensive collection of research evidence and articles relating to Alzheimer’s disease including clinical guidelines, systematic reviews, synopses, clinical trials and case reports.

Top results for alzheimer

161. Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model

Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model Kasuya M, Meguro K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) : The measure of benefit was quality-adjusted life-years (QALYs), which were discounted at a rate of 3%. Cost data: The direct medical costs included medications, out-patient visits, and medical care for patients with Alzheimer’s disease. The values for medications and visits were estimated from published national sources. Assumptions for resource use were made and the costs were based on fees in hospitals with more than 200 beds, and pharmacies filling more than 4,000 prescriptions. The care costs were

NHS Economic Evaluation Database.2010

162. Cost effectiveness of memantine in Alzheimer's disease in the UK

Cost effectiveness of memantine in Alzheimer's disease in the UK Cost effectiveness of memantine in Alzheimer's disease in the UK Cost effectiveness of memantine in Alzheimer's disease in the UK Rive B, Grishchenko M, Guilhaume-Goulant C, Katona C, Livingston G, Lamure M, Toumi M, Francois C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study objective was to assess the cost-effectiveness of memantine for treatment of moderate to severe Alzheimer’s disease. The authors concluded that memantine could be regarded as a cost-effective treatment. The study methodology was good and the methods and results were reported adequately. Given the scope of the study, the authors’ conclusions appear valid. Type of economic

NHS Economic Evaluation Database.2010

163. B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review

B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review Dangour AD, Whitehouse PJ, Rafferty K, Mitchell SA, Smith L, Hawkesworth S, Vellas B CRD summary The authors concluded that there was insufficient (...) evidence to draw definitive conclusion on the effect of B vitamins and fatty acids for the treatment of cognitive decline, dementia and Alzheimer’s Disease. The authors’ cautious conclusions reflect the limited evidence presented and are likely to be reliable. Authors' objectives To evaluate the effectiveness of B-Vitamins and fatty acids in the prevention and treatment of Alzheimer’s Disease and other forms of dementia. Searching PubMed, EMBASE and The Cochrane Library were searched to July 2007

DARE.2010

164. Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study).

Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study). 20522656 2010 06 04 2010 06 22 2016 12 15 1756-1833 340 2010 Jun 03 BMJ (Clinical research ed.) BMJ Effectiveness of a specific care plan in patients with Alzheimer's disease: cluster randomised trial (PLASA study). c2466 10.1136/bmj.c2466 bmj.c2466 To test the effectiveness of a comprehensive specific care plan in decreasing the rate of functional decline in patients with mild (...) to moderate Alzheimer's disease compared with usual care in memory clinics. Cluster randomised trial. 50 memory clinics in France. Patients with Alzheimer's disease (mini-mental state examination score 12-26). 1131 patients were included: 574 from 26 clinics in the intervention group, and 557 from 24 clinics in the usual care (control) group. Memory clinics were the unit of randomisation. The intervention included a comprehensive standardised twice yearly consultation for patients and their caregivers

BMJ2010 Full Text: Link to full Text with Trip Pro

165. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.

Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. 21045096 2010 11 03 2010 11 04 2016 12 15 1538-3598 304 17 2010 Nov 03 JAMA JAMA Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. 1903-11 10.1001/jama.2010.1510 Docosahexaenoic acid (DHA) is the most abundant long-chain polyunsaturated fatty acid in the brain. Epidemiological studies suggest that consumption of DHA is associated with a reduced (...) incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology. To determine if supplementation with DHA slows cognitive and functional decline in individuals with Alzheimer disease. A randomized, double-blind, placebo-controlled trial of DHA supplementation in individuals with mild to moderate Alzheimer disease (Mini-Mental State Examination scores, 14-26) was conducted between November 2007 and May 2009 at 51 US clinical research sites

JAMA2010 Full Text: Link to full Text with Trip Pro

166. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.

Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. CONTEXT: The adipokine leptin facilitates long-term potentiation and synaptic plasticity in the hippocampus, promotes beta-amyloid clearance, and improves memory function in animal models of aging and Alzheimer disease (AD). OBJECTIVE: To relate baseline circulating leptin concentrations in a community-based sample of individuals without dementia to incident dementia and AD during follow-up

JAMA2009 Full Text: Link to full Text with Trip Pro

167. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.

DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model. CONTEXT: DNA beta-amyloid(1-42) (Abeta42) trimer immunization was developed to produce specific T helper 2 cell (T(H)2)-type antibodies to provide an effective and safe therapy for Alzheimer disease (AD) by reducing elevated levels of Abeta42 peptide that occur in the brain of patients with AD. OBJECTIVE: To compare the immune response in wild-type mice after immunization with DNA Abeta42 trimer

JAMA2009 Full Text: Link to full Text with Trip Pro

168. Physical activity, diet, and risk of Alzheimer disease.

Physical activity, diet, and risk of Alzheimer disease. CONTEXT: Both higher adherence to a Mediterranean-type diet and more physical activity have been independently associated with lower Alzheimer disease (AD) risk but their combined association has not been investigated. OBJECTIVE: To investigate the combined association of diet and physical activity with AD risk. DESIGN, SETTING, AND PATIENTS: Prospective cohort study of 2 cohorts comprising 1880 community-dwelling elders without dementia

JAMA2009 Full Text: Link to full Text with Trip Pro

169. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. CONTEXT: Small single-center studies have shown that cerebrospinal fluid (CSF) biomarkers may be useful to identify incipient Alzheimer disease (AD) in patients with mild cognitive impairment (MCI), but large-scale multicenter studies have not been conducted. OBJECTIVE: To determine the diagnostic accuracy of CSF beta-amyloid(1-42) (Abeta42), total tau protein (T-tau), and tau phosphorylated at position

JAMA2009

170. Biracial population study of mortality in mild cognitive impairment and Alzheimer disease

Biracial population study of mortality in mild cognitive impairment and Alzheimer disease 19506138 2009 06 09 2009 08 03 2017 02 20 1538-3687 66 6 2009 Jun Archives of neurology Arch. Neurol. Biracial population study of mortality in mild cognitive impairment and Alzheimer disease. 767-72 10.1001/archneurol.2009.80 To assess mortality associated with mild cognitive impairment (MCI) and Alzheimer disease (AD) among older African Americans and whites from an urban community. Longitudinal (...) Americans vs whites. In the MCI and AD groups, the association of cognitive impairment with survival was stronger for perceptual speed than for other cognitive functions. The presence and severity of MCI and AD are associated with reduced survival among African Americans, and these effects are comparable to those seen among whites. Wilson Robert S RS Rush Alzheimer's Disease Center, Rush University Medical Center, 600 S Paulina Ave, Ste 1038, Chicago, IL 60612, USA. rwilson@rush.edu Aggarwal Neelum T NT

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

171. Self administered cognitive screening test (TYM) for detection of Alzheimer's disease: cross sectional study.

Self administered cognitive screening test (TYM) for detection of Alzheimer's disease: cross sectional study. OBJECTIVE: To evaluate a cognitive test, the TYM ("test your memory"), in the detection of Alzheimer's disease. DESIGN: Cross sectional study. SETTING: Outpatient departments in three hospitals, including a memory clinic. PARTICIPANTS: 540 control participants aged 18-95 and 139 patients attending a memory clinic with dementia/amnestic mild cognitive impairment. INTERVENTION: Cognitive (...) test designed to use minimal operator time and to be suitable for non-specialist use. MAIN OUTCOME MEASURES: Performance of normal controls on the TYM. Performance of patients with Alzheimer's disease on the TYM compared with age matched controls. Validation of the TYM with two standard tests (the mini-mental state examination (MMSE) and the Addenbrooke's cognitive examination-revised (ACE-R)). Sensitivity and specificity of the TYM in the detection of Alzheimer's disease. RESULTS: Control

BMJ2009 Full Text: Link to full Text with Trip Pro

172. Effects of cranial electrical stimulation on sleep disturbances, depressive symptoms, and caregiving appraisal in spousal caregivers of persons with Alzheimer`s disease

Effects of cranial electrical stimulation on sleep disturbances, depressive symptoms, and caregiving appraisal in spousal caregivers of persons with Alzheimer`s disease 19427574 2009 05 11 2009 07 23 2017 02 20 1532-8201 22 2 2009 May Applied nursing research : ANR Appl Nurs Res Effects of cranial electrical stimulation on sleep disturbances, depressive symptoms, and caregiving appraisal in spousal caregivers of persons with Alzheimer's disease. 119-25 10.1016/j.apnr.2007.06.001 The purpose (...) ):193-213 2748771 J Psychiatr Res. 1982-1983;17(1):37-49 7183759 Aged Alzheimer Disease nursing Caregivers psychology Depression nursing therapy Double-Blind Method Electric Stimulation Female Humans Male Pilot Projects Skull Sleep Wake Disorders nursing therapy Spouses Treatment Outcome NIHMS119710 PMC2713101 2007 02 26 2007 06 07 2007 06 07 2009 5 12 9 0 2009 5 12 9 0 2009 7 25 9 0 ppublish 19427574 S0897-1897(07)00091-2 10.1016/j.apnr.2007.06.001 PMC2713101 NIHMS119710

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

173. Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment

Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment 19201945 2009 03 31 2009 04 22 2017 02 20 1527-1315 251 1 2009 Apr Radiology Radiology Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. 195-205 10.1148/radiol.2511080924 To use structural magnetic resonance (MR) images to identify a pattern (...) of regional atrophy characteristic of mild Alzheimer disease (AD) and to investigate whether presence of this pattern prospectively can aid prediction of 1-year clinical decline and increased structural loss in mild cognitive impairment (MCI). The study was conducted with institutional review board approval and compliance with HIPAA regulations. Written informed consent was obtained from each participant. High-throughput volumetric segmentation and cortical surface reconstruction methods were applied

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

174. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures

Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures 19289740 2009 03 17 2009 04 10 2016 11 22 1526-632X 72 11 2009 Mar 17 Neurology Neurology Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. 999-1007 10.1212/01.wnl.0000344568.09360.31 To investigate the added value of hippocampal atrophy rates over whole brain volume measurements on MRI in patients with Alzheimer disease (AD), patients with mild cognitive (...) mild cognitive impairment (MCI) from controls. Whole brain atrophy rate discriminates Alzheimer disease (AD) from MCI. Regional measures of hippocampal atrophy are the strongest predictors of progression to AD. Henneman W J P WJ Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands. w.henneman@vumc.nl Sluimer J D JD Barnes J J van der Flier W M WM Sluimer I C IC Fox N C NC Scheltens P P Vrenken H H Barkhof F F eng G0601846 Medical Research Council United Kingdom Journal

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

175. Pharmaceutical and non-pharmaceutical interventions for Alzheimer's Disease, a rapid assessment

Pharmaceutical and non-pharmaceutical interventions for Alzheimer's Disease, a rapid assessment Pharmaceutical and non-pharmaceutical interventions for Alzheimer's Disease, a rapid assessment Pharmaceutical and non-pharmaceutical interventions for Alzheimer's Disease, a rapid assessment Hulstaert F, Thiry N, Eyssen M, Vrijens F Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation Hulstaert F, Thiry N, Eyssen M, Vrijens F. Pharmaceutical and non-pharmaceutical interventions for Alzheimer's Disease, a rapid assessment. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 111C. 2009 Authors' conclusions From the reviews of the literature and the economic evaluations examined here, it appears that the cost-effectiveness studies on the use of donepezil in AD patients have reported a variety of conclusions with studies

Health Technology Assessment (HTA) Database.2009

176. Ginseng for cognitive function in Alzheimer's disease: a systematic review

Ginseng for cognitive function in Alzheimer's disease: a systematic review Ginseng for cognitive function in Alzheimer's disease: a systematic review Ginseng for cognitive function in Alzheimer's disease: a systematic review Lee MS, Yang EJ, Kim JI, Ernst E CRD summary The authors concluded that there was insufficient evidence that ginseng ( Panax ginseng herb) was an effective treatment for Alzheimer's disease, and that further research is needed. Given the small number and low quality (...) of available trials, the authors' cautious conclusions appear to be reliable. Authors' objectives To assess the effectiveness of ginseng ( Panax ginseng herb) on the cognitive function of patients with Alzheimer's disease. Searching The following databases were searched, up to January 2009, for articles in any language: MEDLINE, EMBASE, AMED, CINAHL, PsycINFO, the Cochrane Library, six Korean Medical databases, four Chinese Medical databases, and Japan Science and Technology Information Aggregator. Search

DARE.2009

177. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine

Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine (...) Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine Rodda J, Morgan S, Walker Z CRD summary This review concluded that the evidence base regarding the efficacy of cholinesterase inhibitors for the behavioural and psychological symptoms of dementia was limited. The cautious conclusions reflected the evidence, but should

DARE.2009

180. Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea

Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea Suh GH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to determine the cost-effectiveness of including galantamine in the treatment of mild-to-moderately severe Alzheimer’s disease, compared with usual care. The authors concluded that usual care plus galantamine was cost-effective compared with usual care alone. The methods were appropriate and both the methods and results were reported adequately

NHS Economic Evaluation Database.2009